Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Age (years) | 1.035 (0.978–1.096) | 0.231 | ||
BMI (kg/m2) | 0.913 (0.773–1.078) | 0.282 | ||
Pre-operative PSA (ng/mL) | ||||
< 20.00 | (reference) | |||
≥ 20.00 | 1.111 (0.551–2.241) | 0.768 | ||
Pre-radiotherapy PSA (ng/mL) | ||||
< 1.00 | (reference) | |||
≥ 1.00 | 0.906 (0.427–1.923) | 0.796 | ||
Pathologic Gleason score | ||||
≤ 7 | (reference) | (reference) | ||
≥ 8 | 2.438 (1.169–5.084) | 0.017 | 1.288 (0.636–2.609) | 0.482 |
Pathologic T stage | ||||
≤ pT2 | (reference) | |||
≥ pT3 | 1.262 (0.599–2.659) | 0.540 | ||
Pathologic N stage | ||||
pN0, or pNx | (reference) | (reference) | ||
pN1 | 6.096 (1.316–28.234) | 0.021 | 16.457 (3.358–80.652) | 0.001 |
Tumor volume (%) | ||||
< 10.0 | (reference) | (reference) | ||
≥ 10.0 | 3.888 (1.923–7.862) | < 0.001 | 4.137 (1.999–8.562) | < 0.001 |
Surgical margin tumor involvement | ||||
Negative | (reference) | |||
Positive | 1.678 (0.819–3.437) | 0.157 | ||
Radiation dose (Gy) | ||||
< 66.0 | (reference) | |||
≥ 66.0 | 1.564 (0.619–3.951) | 0.344 | ||
Testosterone nadir after RP (ng/mL) | 1.170 (0.834–1.643) | 0.363 | ||
Duration of unrecovered testosterone level (months) | 1.002 (0.989–1.015) | 0.802 | ||
Concurrent ADT | ||||
No | (reference) | |||
Yes | 1.134 (0.563–2.287) | 0.725 | ||
Salvage ADT | ||||
No | (reference) | (reference) | ||
Yes | 0.344 (0.171–0.692) | 0.003 | 0.306 (0.150–0.627) | 0.001 |